Neurelis, which submitted an NDA for its Valtoco diazepam nasal spray in September 2018, has announced the appointments of a number of senior management personnel in anticipation of a launch. The appointments announced took place from late 2017 to 2019.
The hires include George Stuart as Chief Financial Officer, Chuck DeWildt as Chief Commercial Officer, Adrian Rabinowicz as Senior VP of Clinical Development & Medical Affairs, Thomas Liquard as Senior VP, Corporate Development, and Steve Jenner as VP of Marketing & Operations.
Valtoco nasal spray (previously known as NRL-1) was granted orphan drug designation in December 2015 and Fast Track designation in December 2016 for the treatment of acute repetitive seizures in epilepsy patients. In December 2018, Neurelis announced that it was acquiring Aegis Therapeutics, which makes Intravail, a key ingredient in the Valtoco formulation.
Neurelis President and CEO Craig Chambliss said, “Over the past two years, we have been incredibly fortunate to add these talented executives to our team at this pivotal time. Their combined track record of building and launching successful commercial, clinical, and development organizations is critical as we prepare for the planned US launch of Valtoco and build our growing CNS pipeline. The unparalleled level of expertise, specifically in the outpatient seizure emergency market, positions Neurelis to significantly benefit the epilepsy community in the very near term.”
Read the Neurelis press release.
